Rigel Pharmaceuticals | RIGL - Equity Capital And Reserves


Rigel Pharmaceuticals reported $117.61M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 465.53M 148.45M Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celldex Therapeutics USD 714.56M 258.34M Jun/2026
Daiichi Sankyo JPY 1.7T 38.53B Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Heron Therapeutics USD 6.91M 2.23M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
Karyopharm Therapeutics USD -265.65M 27.28M Mar/2026
Ligand Pharmaceuticals USD 967.52M 29.81M Jun/2026
MacroGenics USD 42.87M 21.68M Jun/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Ultragenyx Pharmaceutical USD -291M 55M Jun/2026
Veracyte USD 1.39B 44M Jun/2026